Ocular immunology and inflammation · 2017
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fabiani Claudia, Sota Jurgen, Vitale Antonio, Emmi Giacomo, Vannozzi Lorenzo, Bacherini Daniela, Lopalco Giuseppe, Guerriero Silvana, Venerito Vincenzo, Orlando Ida, Franceschini Rossella, Fusco Fiorella, Frediani Bruno, Galeazzi Mauro, Iannone Florenzo, Tosi Gian Marco, Cantarini Luca
Аннотация
PURPOSE: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet's disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment.
METHODS: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves.
RESULTS: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001).
CONCLUSIONS: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.
METHODS: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves.
RESULTS: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001).
CONCLUSIONS: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.